Open an account

Integra Lifesciences Holdings

IART · NASDAQ

$13.33−$0.12 (−0.89%)TodayMarket closed ·
Prev close $13.45

About IART

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. The company is headquartered in Princeton, New Jersey and currently employs 4,427 full-time employees. The company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). CSS consists of technologies and instrumentations used for specialties, such as neurosurgery, neurocritical care, and otolaryngology. CSS neurosurgical business includes a portfolio of brands, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The company provides instruments that are used in precision, specialty and general surgical procedures. TT includes Wound Reconstruction and Care business, which sells offerings, such as skin and wound repair, plastics and surgical reconstruction products and nerve and tendon repair products. Its products include CUSA Platform, Codman Neurosurgical Accessories, DuraGen Dural Graft Matrix, DuraSeal Dural Sealant System and others.

Employees
4,427
Headquarters
Princeton, New Jersey
Listed
Aug 16, 1995
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
integralife.com

IART key statistics

Market cap
1.04B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.09M
Volume
1.31M
Open price
$13.51
High today
$13.76
Low today
$13.27
52 Week high
$20.49
52 Week low
$8.70

Integra Lifesciences Holdings (IART) at a glance

As of Oct 20, 2026, Integra Lifesciences Holdings (IART) shares are priced at $13.33, giving the company a market cap of 1.04B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $13.27 and $13.76. The current price is 0.5% above the day's low and 3.1% below its high.

Volume so far is 1.31M shares, in line with the average of 1.09M shares a day.

Over the past year Integra Lifesciences Holdings has ranged from $8.70 to $20.49, and now sits 39% of the way up that range.

Integra Lifesciences Holdings met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $0.56 per share against an estimate of $0.4931.

The average analyst price target is $20.27, 52.1% above the current price, from 7 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 7 analyst ratings say Buy
  • Buy0.0%
  • Hold85.7%
  • Sell14.3%
Price target · 11 analystsAvg $20.27
Low
$14.14
Now
$13.33
High
$28.35

IART earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 12.1% on average.

  1. Q3 FY24: reported $0.41 per share against an estimate of $0.3972
  2. Q4 FY24: reported $0.97 per share against an estimate of $0.8729
  3. Q1 FY25: reported $0.41 per share against an estimate of $0.4397
  4. Q2 FY25: reported $0.45 per share against an estimate of $0.4402
  5. Q3 FY25: reported $0.54 per share against an estimate of $0.4437
  6. Q4 FY25: reported $0.83 per share against an estimate of $0.8163
  7. Q1 FY26: reported $0.54 per share against an estimate of $0.4126
  8. Q2 FY26: reported $0.56 per share against an estimate of $0.4931

IART news

  • Press releaseGlobe Newswire

    Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting

  • Press releaseBusiness Wire

    INTEGRA LIFESCIENCES HOLDINGS CORPORATION IART INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 21.2% Share Drop

  • Press releaseGlobe Newswire

    INTEGRA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Integra LifeSciences Holdings Corporation on Behalf of Integra Stockholders and Encourages Investors to Contact the Firm

  • Press releaseGlobe Newswire

    Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026

  • Press releasePRNewswire

    Nasdaq Hits Fresh Highs While Dow Slips and Small Caps Struggle for Direction

  • Vandana Singh

    Flood Damage Prompts Integra LifeSciences To Revise 2026 Outlook

  • Press releaseGlobe Newswire

    Integra LifeSciences (NASDAQ: IART) Investor Alert: Johnson Fistel Investigates Following Flooding-Related Outlook Cuts and 21% Stock Decline

  • Press releasePRNewswire

    Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week

Similar companies

Companies in the same industry as Integra Lifesciences Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.